Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT.

ABSTRACT:

Abstract

The current approach to minimize transplant-associated complications, including graft-versus-host disease (GVHD) includes long-term pharmacological immune suppression frequently accompanied by unwanted side effects. Advances in targeted immunotherapies regulating alloantigen responses in the recipient continue to reduce the need for pan-immunosuppression. Here, in vivo targeting of the tumor necrosis factor superfamily receptor TNFRSF25 (also known as DR3) and the high-affinity interleukin-2 (IL-2) receptor with a TL1A-immunoglobulin (TL1A-Ig) fusion protein and low-dose IL-2, respectively, was used to pretreat recipient mice before allogeneic hematopoietic stem cell transplantation (aHSCT). Pretreatment induced regulatory T cell (Treg) expansion persisting 1 to 2 weeks af

SUBMITTER: McManus D 

PROVIDER: S-EPMC12809230 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature